A 52-year-old woman with HIV took efavirenz-tenofovir DF-emtricitabine for about 10 years and has maintained an undetectable HIV RNA level. She recently switched to bictegravir-tenofovir alafenamide-emtricitabine. She has maintained virologic suppression on this regimen but has gained 11 pounds in the past 14 months. She denies major changes in dietary habits or activity level.
Which one of the following statements is TRUE about integrase strand transfer inhibitors (INSTIs) and weight gain?

Figure 1. Weight Gain following Initiation of Antiretroviral Therapy
This retrospective observational cohort study analyzed data from 1,152 persons following their initiation of antiretroviral therapy. This included 351 persons receiving an integrase strand transfer inhibitor (135 on dolutegravir, 153 elvitegravir, and 63 raltegravir).
Source: Bourgi K, Rebeiro PF, Turner M, et al. Greater Weight Gain in Treatment-naive Persons Starting Dolutegravir-based Antiretroviral Therapy. Clin Infect Dis. 2020;70:1267-74.
Sign In or Register Progress Not Saved!
Since you are not signed in, your progress won't be saved.
Since you are not signed in, your progress won't be saved.
Question Last Updated
January 28th, 2025
January 28th, 2025
Steps to Acquire CE for this Question Bank Topic:
1
Answer
Answer all questions
2
Score 80%+
Answer correctly
3
Claim CE
Choose CNE or CME
4
Give Feedback
Complete survey
5